価格表

在庫・価格 : 2025年04月26日 12時52分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Rox Factor XIa Kit (2x50tests) <Activated Factor XI, Human, Chromogenic Activity Assay Kit>
データシート※最新のデータシートでない場合があります
110050 ROXロシックス
Rossix AB
1 kit ¥69,000
(未発注)
追加

在庫・価格 : 2025年04月26日 12時52分 現在

Rox Factor XIa Kit (2x50tests) <Activated Factor XI, Human, Chromogenic Activity Assay Kit>

  • 商品コード:110050
  • メーカー:ROX
  • 包装:1kit
  • 価格: ¥69,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Alonso W et al. Immune globulin subcutaneous, human 20% solution (Xembify&#xAE;), a new high concentration immunoglobulin product for subcutaneous administration. Biologicals 2020 Mar;64:34-40
Alonso W et al
2020/01/01
PubMed
2 Persson E et al. Reagent-specific underestimation of turoctocog alfa pegol (N8-GP) clotting activity owing to decelerated activation by thrombin. Res Pract Thromb Haemost 2019 Jan;3(1):114-120
Persson E et al
2019/01/01
PubMed
3 Stroo I et al. Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XI. Thromb Haemost 2018 02;118(2):340-350
Stroo I et al
2018/01/01
PubMed
4 Ros辿n S. New Tools to Study Contact Activation. Front Med (Lausanne) 2016;3:58
Ros辿n S
2016/01/01
PubMed
5 Park DH et al. A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations. Biologicals 2017 Jan;45:1-8
Park DH et al
2017/01/01
PubMed
6 Ros辿n P et al. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX. J Thromb Haemost 2016 07;14(7):1420-7
Ros辿n P et al
2016/01/01
PubMed
7 Hansson KM et al. The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood. J Thromb Haemost 2014 Oct;12(10):1678-86
Hansson KM et al
2014/01/01
PubMed
  • No.: 1
  • 文献情報:
    Alonso W et al. Immune globulin subcutaneous, human 20% solution (Xembify&#xAE;), a new high concentration immunoglobulin product for subcutaneous administration. Biologicals 2020 Mar;64:34-40
    Alonso W et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Persson E et al. Reagent-specific underestimation of turoctocog alfa pegol (N8-GP) clotting activity owing to decelerated activation by thrombin. Res Pract Thromb Haemost 2019 Jan;3(1):114-120
    Persson E et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Stroo I et al. Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XI. Thromb Haemost 2018 02;118(2):340-350
    Stroo I et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Ros辿n S. New Tools to Study Contact Activation. Front Med (Lausanne) 2016;3:58
    Ros辿n S
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Park DH et al. A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations. Biologicals 2017 Jan;45:1-8
    Park DH et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Ros辿n P et al. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX. J Thromb Haemost 2016 07;14(7):1420-7
    Ros辿n P et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Hansson KM et al. The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood. J Thromb Haemost 2014 Oct;12(10):1678-86
    Hansson KM et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed